Tenenbaum J
Mount Sinai Hospital, Toronto, Canada.
Can J Gastroenterol. 1999 Mar;13(2):119-22. doi: 10.1155/1999/361651.
Nonsteroidal anti-inflammatory drug (NSAID) use has increased dramatically in the past two decades. A large proportion of the elderly population (more than 65 years of age) holds a current or recent NSAID prescription, accounting for approximately 90% of all NSAID prescriptions. Despite studies that advise finding alternatives for NSAIDs for the management of osteoarthritis, physicians often prescribe NSAIDs first for such common musculoskeletal conditions. Despite being identified as risk factors for gastrointestinal complications, the simultaneous use of two NSAIDs and the coadministration of NSAIDs with corticosteroids and with coumadin continue to occur. The point prevalence of NSAID-induced ulcers is 10% to 30%, and 15% to 35% of all peptic ulcer complications are caused by NSAIDs. The increased risk of gastrointestinal complications when NSAIDs are used is 3% to 5%. This risk increases with other identified risk factors (eg, older age, previous gastrointestinal history, comorbid diseases and poor health). Gastrointestinal causes of hospitalization (eg, gastrointestinal hemorrhage and perforation) and death have increased in parallel to increased NSAID use. 'Antiulcer' agents are prescribed twice as often in NSAID users, and the economic impact (eg, diagnostic tests and hospitalization) is that about one-third of the arthritis budget has been dedicated to deal with gastrointestinal side effects of NSAIDs. Misoprostol and omeprazole have been shown to be cytoprotective for the gastroduodenal mucosa when NSAIDs are used, and misoprostol has been shown to reduce the risk of gastroduodenal ulcer complications. Economic evaluations have suggested that these agents are a cost effective means of dealing with such NSAID-associated problems. Although no NSAID is totally safe, a number of studies have demonstrated that NSAIDs may be ranked according to relative gastrointestinal toxicity. The role of Helicobacter pylori in NSAID-associated problems remains uncertain.
在过去二十年中,非甾体抗炎药(NSAID)的使用急剧增加。很大一部分老年人群(65岁以上)目前正在使用或近期使用过NSAID处方,约占所有NSAID处方的90%。尽管有研究建议为骨关节炎的治疗寻找NSAID的替代药物,但医生在治疗此类常见肌肉骨骼疾病时通常首先开具NSAID。尽管同时使用两种NSAID以及NSAID与皮质类固醇和香豆素联合使用被确定为胃肠道并发症的危险因素,但这种情况仍在继续发生。NSAID引起的溃疡的时点患病率为10%至30%,所有消化性溃疡并发症中有15%至35%是由NSAID引起的。使用NSAID时胃肠道并发症的风险增加3%至5%。随着其他已确定的危险因素(如年龄较大、既往胃肠道病史、合并疾病和健康状况不佳),这种风险会增加。与NSAID使用增加并行的是,因胃肠道原因住院(如胃肠道出血和穿孔)和死亡的情况有所增加。NSAID使用者中“抗溃疡”药物的处方频率是其他人的两倍,经济影响(如诊断检查和住院)是关节炎预算的约三分之一已用于处理NSAID的胃肠道副作用。已证明米索前列醇和奥美拉唑在使用NSAID时对胃十二指肠黏膜具有细胞保护作用,并且米索前列醇已被证明可降低胃十二指肠溃疡并发症的风险。经济评估表明,这些药物是处理此类NSAID相关问题的一种具有成本效益的手段。虽然没有一种NSAID是完全安全的,但多项研究表明,NSAID可根据相对胃肠道毒性进行排名。幽门螺杆菌在NSAID相关问题中的作用仍不确定。